- Home
- OTLK vs FLYX Comparison
OTLK vs FLYX Comparison
Compare OTLK & FLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- FLYX
- Stock Information
- Founded
- OTLK 2010
- FLYX 2015
- Country
- OTLK United States
- FLYX United States
- Employees
- OTLK N/A
- FLYX N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- FLYX Blank Checks
- Sector
- OTLK Health Care
- FLYX Finance
- Exchange
- OTLK Nasdaq
- FLYX Nasdaq
- Market Cap
- OTLK 48.3M
- FLYX 39.4M
- IPO Year
- OTLK 2016
- FLYX N/A
- Fundamental
- Price
- OTLK $2.22
- FLYX $2.91
- Analyst Decision
- OTLK Strong Buy
- FLYX
- Analyst Count
- OTLK 5
- FLYX 0
- Target Price
- OTLK $9.60
- FLYX N/A
- AVG Volume (30 Days)
- OTLK 901.8K
- FLYX 12.3K
- Earning Date
- OTLK 08-22-2025
- FLYX 08-13-2025
- Dividend Yield
- OTLK N/A
- FLYX N/A
- EPS Growth
- OTLK N/A
- FLYX N/A
- EPS
- OTLK 0.83
- FLYX N/A
- Revenue
- OTLK N/A
- FLYX $335,427,000.00
- Revenue This Year
- OTLK N/A
- FLYX $28.47
- Revenue Next Year
- OTLK $407.74
- FLYX $22.44
- P/E Ratio
- OTLK $2.58
- FLYX N/A
- Revenue Growth
- OTLK N/A
- FLYX 5.38
- 52 Week Low
- OTLK $0.87
- FLYX $1.79
- 52 Week High
- OTLK $8.32
- FLYX $4.90
- Technical
- Relative Strength Index (RSI)
- OTLK 50.39
- FLYX 63.19
- Support Level
- OTLK $1.79
- FLYX $2.16
- Resistance Level
- OTLK $2.24
- FLYX $2.60
- Average True Range (ATR)
- OTLK 0.13
- FLYX 0.27
- MACD
- OTLK -0.00
- FLYX 0.06
- Stochastic Oscillator
- OTLK 45.05
- FLYX 91.91
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.